Medical Doctor Program year 2025 Reported 2020–2025 Source: CMS Open Payments, 2026 publication

Michael Hamer

Neurology Opelika, AL Medical Doctor

NPI 1851745335 CMS profile 8799543

2570 Village Professional Dr, Opelika, AL 36801

Open in the dashboard

General payments

$4,735

269 records reported · program years 2020–2025

Research payments

$0

Paid to them · None reported · program years 2020–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Michael Hamer of Opelika, AL is reported in the CMS Open Payments database as having received $4,735 across 269 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 65th percentile of Neurology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,173 79
2024 General $1,098 53
2023 General $604 36
2022 General $711 40
2021 General $888 46
2020 General $262 15

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Michael Hamer
  • Neurology median
  • Middle half of Neurology
  • National median

In program year 2025, general payments to Michael Hamer were reported at $1,173. Among 11,022 Neurology profiles paid that year, the median was $457 and the middle half received between $118 and $2,344.

Show as a table
Year Michael Hamer Neurology median Middle half National median
2019 $0 $474 $118–$2,177 $163
2020 $262 $367 $82–$2,309 $114
2021 $888 $438 $104–$2,547 $132
2022 $711 $442 $103–$2,388 $149
2023 $604 $464 $119–$2,312 $160
2024 $1,098 $468 $119–$2,323 $164
2025 $1,173 $457 $118–$2,344 $169

Breakdown

Who paid General payments · program years 2020–2025
  1. AbbVie, Inc. $1,291 79 payments
  2. Biogen, Inc. $594 39 payments
  3. Pfizer Inc. $360 33 payments
  4. ACADIA Pharmaceuticals Inc $287 13 payments
  5. Teva Pharmaceuticals USA, Inc. $203 11 payments
  6. Janssen Pharmaceuticals, Inc $201 6 payments
  7. Amgen Inc. $197 10 payments
  8. UCB, Inc. $156 6 payments
  9. Lilly USA, LLC $151 8 payments
  10. Argenx US, Inc. $145 5 payments
  11. Other $1,153 59 payments

Every payment, record by record

What the payments were for General payments · program years 2020–2025
  1. Food and Beverage $4,596 267 payments
  2. Education $139 2 payments
Products named General payments · program years 2020–2025
  1. UBRELVY $931 54 payments
  2. QULIPTA $457 27 payments
  3. TYSABRI $393 29 payments
  4. NURTEC ODT $308 30 payments
  5. ZAVZPRET $308 30 payments
  6. VUMERITY Neurology $267 22 payments
  7. NUPLAZID $195 9 payments
  8. BOTOX $172 12 payments
  9. VUMERITY Neurology $167 10 payments
  10. Briviact $156 6 payments
  11. Other $2,577 131 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 59 drugs

Part D claims

2,922

Median for Neurology: 833

Drug cost

$1,086,347

Median for Neurology: $202,670

Branded share of claims

35.6%

Median for Neurology: 25.9%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Privigen Immun Glob G(Igg)/Pro/Iga 0-50 Brand 42 $209,655
Austedo Deutetrabenazine Brand 21 $195,771
Ingrezza Valbenazine Tosylate Brand 14 $109,722
Nuplazid Pimavanserin Tartrate Brand 11 $91,089
Ubrelvy Ubrogepant Brand 61 $81,556
Nurtec Odt Rimegepant Sulfate Brand 44 $77,869
Qulipta Atogepant Brand 59 $75,175
Aimovig Autoinjector Erenumab-Aooe Brand 76 $73,559
Carbidopa-Levodopa Carbidopa/Levodopa Brand 314 $19,233
Nuedexta Dextromethorphan Hbr/Quinidine Brand 11 $16,729

The 10 drugs with the highest cost, of 59 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 13,695 Part D prescribers listed as Neurology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 17 billing codes

Paid by Medicare

$56,116

Medicare's payments for the services billed

Medicare patients

485

Average age 74

Services billed

912

263 women, 222 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 56%
Ischemic heart disease 38%
Depression 34%
Diabetes 33%
Chronic kidney disease 25%
Alzheimer's or dementia 24%
Atrial fibrillation 22%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 21 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
UBRELVY
  • AbbVie, Inc. $479
$479 61 —
QULIPTA
  • AbbVie, Inc. $105
$105 59 —
BOTOX
  • AbbVie, Inc. $67
$67 — —
OCREVUS
  • Genentech USA, Inc. $61
$61 — —
Briviact
  • UCB, Inc. $29
$29 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 21 in the dashboard with a free account

Records

269 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Neurology in Alabama

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record